166 related articles for article (PubMed ID: 31104010)
1. Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy.
Serilmez M; Özgür E; Karaman S; Gezer U; Duranyıldız D
Cancer Biomark; 2019; 25(2):177-184. PubMed ID: 31104010
[TBL] [Abstract][Full Text] [Related]
2. Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.
Zhang N; Xie F; Gao W; Yu S; Qiu L; Lin W; Sun Y; Jia T
Mol Med Rep; 2015 Apr; 11(4):2797-804. PubMed ID: 25504327
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression.
Noguchi E; Saito N; Kobayashi M; Kameoka S
Mol Med Rep; 2015 May; 11(5):3423-31. PubMed ID: 25592281
[TBL] [Abstract][Full Text] [Related]
4. Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Jia Y; Li X; Zhao C; Jiang T; Zhao S; Zhang L; Liu X; Shi J; Qiao M; Luo J; Liu S; Han R; Chen X; Zhou C
Lung Cancer; 2018 Nov; 125():22-28. PubMed ID: 30429024
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
[TBL] [Abstract][Full Text] [Related]
6. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
7. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
Li Y; Huang X; Zhang J; Li Y; Ma K
Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
[TBL] [Abstract][Full Text] [Related]
8. Plasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patients.
Hosoda H; Izumi H; Tukada Y; Takagiwa J; Chiaki T; Yano M; Arai H
Ann Thorac Cardiovasc Surg; 2012; 18(1):1-7. PubMed ID: 21959198
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
10. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development.
Ekert JE; Johnson K; Strake B; Pardinas J; Jarantow S; Perkinson R; Colter DC
PLoS One; 2014; 9(3):e92248. PubMed ID: 24638075
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Uramoto H; Yamada T; Yano S; Kondo N; Hasegawa S; Tanaka F
Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
14. The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?
Passiglia F; Van Der Steen N; Raez L; Pauwels P; Gil-Bazo I; Santos E; Santini D; Tesoriere G; Russo A; Bronte G; Zwaenepoel K; Cappuzzo F; Rolfo C
Curr Drug Targets; 2014; 15(14):1284-92. PubMed ID: 25511614
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
16. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
17. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
18. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.
Kanteti R; Yala S; Ferguson MK; Salgia R
J Environ Pathol Toxicol Oncol; 2009; 28(2):89-98. PubMed ID: 19817696
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Fujikawa H; Matsushita K; Okugawa Y; Inoue Y; Uchida K; Mohri Y; Kusunoki M
Int J Oncol; 2012 Feb; 40(2):583-91. PubMed ID: 21922134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
